期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

经皮冠状动脉介入治疗围手术期强化他汀药物治疗机制的初步探讨 被引量：5

下载PDF
导出
摘要 ARMYDA和NAPLES系列研究提示,经皮冠状动脉介入治疗(PCI)术前给予大剂量他汀药物治疗,可以显著降低围手术期心肌梗死和30天主要心脏不良事件的发生率。PCI可导致血管内皮损伤,加重炎症反应。围手术期强化他汀治疗带来的获益主要来自于他汀药物的生物学多效性,可能机制包括抗炎症反应、改善血管内皮功能,抗栓作用,扩张冠状动脉微血管等调脂以外的作用。强化他汀治疗还可以降低对比剂肾病的发生率,对于改善患者的远期预后起到积极的作用。
作者 郭静萱 刘健
机构地区 北京大学第三医院心内科 北京大学人民医院心内科
出处 《中国循环杂志》 CSCD 北大核心 2010年第2期81-83,共3页 Chinese Circulation Journal
关键词 经皮冠状动脉介入治疗 围手术期 强化他汀治疗
分类号 R541.4 [医药卫生—心血管疾病]
  • 相关文献

参考文献21

  • 1Briguoria C, Colombob A,Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J ,2004,25 : 1822-1828.
  • 2Pasceri V, Patti G, Nusea A,et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA ( Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation ,2004,110:674-678.
  • 3Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coil Cardiol,2007,49:1272-1278.
  • 4Briguori C, Visconti G, Focaccio A, et al. Novel Approaches for Preventing or Limiting Events(Naples) II Trial : Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction. J Am Coll Cardiol,2009,54(23 ) :2157-2163.
  • 5Sciascio GD, Patti G, Pasceri V, et al. Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty)Randomized Trial. J Am Coil Cardiol,2009, 54 : 558-565.
  • 6Hao PP, Chen YG,Wang JL, et al. Meta-analysis of the Role of High-dose Statins Administered Prior to PCI in Reducing MACE in Patients with Coronary Artery Disease. Clin Exp Pharmacol Physiol,2009,23. [ Epub ahead of print].
  • 7Serrano CV Jr, Ramires JA, Venturinelli M,et al. Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression: evidence of inflammatory responses in coronary angioplasty. J Am Coll Cardiol, 1997,29:1276-1283.
  • 8Bonz AW,Lengenfelder B ,Jacobs M ,et al. Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein Ⅱb/Ⅲa receptor antagonism. Am Heart J,2003,1,45:693-699.
  • 9Boos C J, Balakrishnan B,Jessani S, et al. Effects of percutaneous coronary intervention on peripheral venous blood circulating endothelial cells and plasma in- dices of endothelial damage/dysfunction. Chest ,2007,132 ;1920-1926.
  • 10Gomes WJ, Buffalo E. Coronary stenting and inflammation: implications for further surgical and medical treatment. Ann Thorac Surg,2006,81:1918-1925.

二级参考文献12

  • 1Aspelin P.Nephrotoxicity and the role of contrast media.Radiat Med,2004,22:377-378.
  • 2Nash K,Hafeez A,Hou S.Hospital-acquired renal insufficiency.Am J Kidney Dis,2002,39:930-936.
  • 3Taylor AJ,Hotehkiss D,Morse RW,et al.PREPARED:Preparation for Angiography in Renal Dysfunction:a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction.Chest,1998,114:1570-1574.
  • 4Mueller C,Buerkle G,Buettner HJ,et al.Prevention of contrast media-associated nephropathy:randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty.Arch Intern Med,2002,162:329-336.
  • 5Shepherd J,Kastelein JJ,Bittner V,et al.Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease:the Treating to New Targets (TNT) study.Clin J Am Soc Nephrol,2007,2:1131-1139.
  • 6王笑云.肾小球功能检查//陈文彬,潘祥林.诊断学.6版.北京:人民卫生出版社,2004:379
  • 7Chello M,Goffredo C,Patti G,Effects of atorvestatin on arterial endothelial function in coronary bypass surgery.Eur J Cardiothorac Surg,2005,28:805-810.
  • 8Patti G,Nusea A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing pereutaneous coronary intervention.Am J Cardiol,2008,101:279-285.
  • 9Dulak J,Loboda A,Jazwa A.Atorvastatin affects several angiogenic mediators in human endothelial cells.Endothelium,2005,12:233-241.
  • 10Bonnet J,McPherson R,Tedgui A,et al.Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease:results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.Clin Ther,2008,30:2298-2313.

共引文献46

同被引文献70

  • 1胡大一.NCEP-ATPIII报告——关于血脂异常干预的重要新建议[J].中国医刊,2004,39(9):62-62. 被引量：2
  • 2苏海华.造影剂肾病的诊疗进展[J].国际移植及血液净化杂志,2006,4(3):1-4.
  • 3Rihal CS, Textor SC, Grill DE, et al. Incidence and prognosticimportance of acute renal failure after percutaneous coronaryintervention[J].Circulation, 2002, 105 (19):2259-2264.
  • 4Toprak 0. Risk markers for contrast induced nephropathy [J].Am JMed Sci, 2007,334(4):283-290.
  • 5Castini D, Lucreziotti S, Bosotti L,et al. Prevention of contrastinduced Nephropathy: a single center randomized study [J].ClinCardiol,2010, 33(3): E63-68.
  • 6Heyman SN, Rosen S,Khamaisi M,et al. Reactive oxygen speciesand the pathogenesis of radiocontrast -induced nephropathy [J].Invest Radiol,2010,45(4): 188-195.
  • 7Melfi R, Nusca A, Patti G, et al. Statins and their role inprepercutaneous coronary intervention [JJ.Cur Cardiol Rep,2010,32(12):295-351.
  • 8Patti G, Ricottini E, Nusca A,et al. Short -term, high -doseAtorvastatin pretreatment to prevent contrast-induced nephropathyin patients with acute coronary syndromes undergoing percutaneouscoronary intervention (from the ARMYDA-CIN [atorvastatin forreduction of myocardial damage during angioplasty -contrast -induced nephropathy] trial)[J].Am J Cardiol, 2011,108(1):1-7.
  • 9Patti G, Nusca A, Chello M,et al. Usefulness of statin pretreatmentto prevent contrast-induced nephropathy and to improve long-termoutcome in patients undergoing percutaneous coronaryintervention[J].Am J Cardiol,2008,101 (3): 279-285.
  • 10Ichiki T,Takeda K,Tokunou T,et al.Downregulation of angiotensoinII type I receptor by hydrophobic 3 -hydroxy -3 -methylglutarylcoenzyme A reductase inhibitors in vascular smooth muscle cells[J].Arterioscler Thromb Vase Biol ,2001, 21 (12):1896-1901.

引证文献5

二级引证文献23

中国循环杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部